Exxel Pharma is a privately held company focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The Company’s lead program, EX937, is a first-in-class, proprietary small molecule being developed for refractory chronic cough, a large underserved market with no current FDA-approved therapies, that affects approximately 10% of the global population. Leveraging a differentiated approach by inhibiting the FAAH enzyme, EX937 has demonstrated efficacy and favorable safety in its ability to modulate chronic cough in preclinical models. The Company is rapidly advancing the development of EX937 towards a first-in-human Phase 1/1b study. EX937 also has the potential to be utilized across a number of blockbuster indications, including hyperactive bladder, peripheral neuropathic pain and migraine headaches.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 12635 E Montview Blvd,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- exxelpharma.com
- Keywords
- Neuronal Hypersensitivity Disorder, Chronic Cough, Hyperactive Bladder, Neuropathic Pain, Migraines.
- HQ
- Aurora, Colorado
Exxel Pharma Questions
Exxel Pharma's website is exxelpharma.com
Exxel Pharma's LinkedIn profile is https://www.linkedin.com/company/exxel-pharma
Exxel Pharma has
4 employees.
View email and phone details for 4
employees at Exxel Pharma.
Exxel Pharma's industry is
Pharmaceutical Manufacturing
Exxel Pharma's top competitors are
Enveda,
Edgewise Therapeutics,
Ambrosia Biosciences Inc.,
Allander Biotechnologies,
Neurexis Therapeutics,
Nexien Biopharma,
Avidity Biosciences, Inc.,
Lohocla Research Corporation,
Arpeggio Biosciences,
Machavert Pharmaceuticals.
Exxel Pharma's categories are Pharmaceutical Manufacturing
Exxel Pharma's founding year is 2017
